Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

SGLT2 inhibitors (eg Canagliflozin)

Source date not recordedAnalyse record ↗

Top scoring candidate for TAME-like trial (see gerotherapeutics score column).

Modality
drug
Availability (US)
by prescription
Kind
age slowing
Gerotherapeutics score
12
Pathologies score
501
Rodent lifespan
+114 days (+14%)
Tested by ITP
yes
ITP year first tested
2016
ITP median % ↑ (♂, best cohort)
14.00
ITP median % ↑ (♀, best cohort)
1.00
ITP P90 % ↑ (♂, best cohort)
9.00
ITP P90 % ↑ (♀, best cohort)
4.00
ITP sex effect
both
ITP dose (ppm)
180 ppm; 60 ppm
ITP age at start (mo)
7 mo; 6 mo; 16 mo; 7 mo until 20 mo
ITP replicated
yes
ITP result status
Published (full stats); In progress

ITP cohort detail (5)

YearCohortDose♂ med♀ med♂ P90♀ P90Citation
2016C2016180 ppm14%1%9%1%↗ paper
2020C2020180 ppm8.8%-1.3%4.5%4%↗ paper
2020C2020180 ppm13.8%-6.1%4.2%-8.2%↗ paper
2023C2023180 ppmNot availableNot availableNot availableNot available↗ paper
2023C202360 ppmNot availableNot availableNot availableNot available↗ paper